Acadia Pharmaceuticals
ACAD
236 hedge funds and large institutions have $3.81B invested in Acadia Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 76 increasing their positions, 76 reducing their positions, and 29 closing their positions.
123% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $5.54M
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
28% more capital invested
Capital invested by funds: $2.97B → $3.81B (+$838M)
17% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 29
1% more funds holding
Funds holding: 233 → 236 (+3)
0.88% more ownership
Funds ownership: 97% → 97.88% (+0.88%)
0% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$51.7M |
| 2 |
RI
RTW Investments
New York
|
+$34.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.5M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$20.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.1M |
| 2 |
JP Morgan Chase
New York
|
-$29M |
| 3 |
Millennium Management
New York
|
-$28.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.2M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$13.2M |
ACAD Hedge Fund Activity: Q2 2023 in Review
236 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2023, worth a combined $3.81B — up 28% from $2.97B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ACAD positions and 29 closed out — a net gain of 5 holders — while 76 added to existing stakes and 76 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $51.7M. The largest seller was Fidelity Investments, cutting an estimated $56.1M.
- 236 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2023, up from 233 in Q1 2023.
- Funds reported $3.81B of Acadia Pharmaceuticals stock for Q2 2023, up 28% quarter-over-quarter.
- 34 funds opened new Acadia Pharmaceuticals positions in Q2 2023 and 29 closed out, a net change of +5 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2023 was Adage Capital Partners, an estimated $51.7M added.
- The largest Acadia Pharmaceuticals seller in Q2 2023 was Fidelity Investments, an estimated $56.1M sold.
Based on aggregated 13F filings for Q2 2023.